Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01016691 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of a Drug Delivery System in Glaucoma
A Phase 2 study, sponsored by Vistakon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT01016691 is a Phase 2 study that has completed, run by Vistakon Pharmaceuticals. The registered enrollment target is 47 participants.
The verdict
NCT01016691, a Phase 2 study, has completed, sponsored by Vistakon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
Evaluation of the ocular safety and efficacy of a drug delivery system in open-angle glaucoma or ocular hypertension.
Interventions
- DRUG bimatoprost 0.03%
- DRUG High Dose Drug Device
- DRUG Low Dose Drug Device
- DRUG Placebo Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01016691
The ClinicalTrials.gov registry entry for NCT01016691 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vistakon Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which bimatoprost 0.03% is the first listed.
NCT01016691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01016691 about?
NCT01016691 is a clinical study titled "Safety and Efficacy of a Drug Delivery System in Glaucoma". Evaluation of the ocular safety and efficacy of a drug delivery system in open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT01016691?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2009-10.
What interventions are being tested in trial NCT01016691?
The interventions under investigation include: bimatoprost 0.03% (DRUG), High Dose Drug Device (DRUG), Low Dose Drug Device (DRUG), Placebo Device (DRUG).
Who is sponsoring clinical trial NCT01016691?
This trial is sponsored by Vistakon Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.